Antidonor antibodies and transplantation: How to deal with them before and after transplantation

Transplantation

Volumn 79, Issue 3 SUPPL., 2005, Pages

  Glotz, Denis ^a   Antoine, Corinne ^a   Duboust, Alain ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ALLOANTIBODY; ANTIIDIOTYPIC ANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GAMMA PEG; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN BCL XL; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY TITER; BK VIRUS; BLOOD GROUP ABO INCOMPATIBILITY; BONE MARROW TRANSPLANTATION; CONFERENCE PAPER; DESENSITIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FOLLOW UP; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEART ASSIST DEVICE; HEART TRANSPLANTATION; HISTOINCOMPATIBILITY; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; JAPAN; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; PLASMAPHERESIS; PRIORITY JOURNAL; PROPHYLAXIS; SPLENECTOMY; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY;

EID: 14344256480     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000153297.11006.13     Document Type: Conference Paper

References (32)

1. Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation 1998; 65: 224.
2. Taylor CJ, Chapman JR, Ting A, and Morris PJ. Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. Transplantation 1989; 48: 953.
3. Scornik JC, Clapp W, Patton PR, et al. Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation 2001; 71: 1098.
4. Kerman RH, Susskind B, Buelow R, et al. Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection. Transplantation 1996; 62: 201.
5. Pollock CA, Mahony JF, Ibels LS, et al. Immunoglobulin abnormalities in renal transplant recipients. Transplantation, 1989; 47: 952.
6. Smith KG, Isbel NM, Catton MG, et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998; 13: 160.
7. Schmid C, Garritsen HS, Kelsch R, et al. Suppression of panel-reactive antibodies by treatment with mycophenolate mofetil. Thorac Cardiovasc Surg 1998; 46: 161.
8. Glotz D, Haymann J-P, Sansonetti N, et al. Suppression of allo-anti HLA antibodies by high dose intravenous immunoglobulins (IVIg): a potential tool for transplantation of immunized patients. Transplantation 1993; 56: 335.
9. John R, Lietz K, Burke E, et al. Intravenous Immunoglobulin Reduces Anti-HLA Alloreactivity and Shortens Waiting Time to Cardiac Transplantation in Highly Sensitized Left Ventricular Assist Device Recipients. Circulation 1999; 100 (19 Suppl): II229.
10. Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553.
11. Nasman Bjork I, Fesel C, Brissac C and Lundkvist I. Prophylactic intravenous immunoglobulin treatment influences serum immunoglobulin M repertoire development after allogeneic bone marrow transplantation. Scand J Immunol 1999; 50: 73.
12. Glotz D, Haymann JP, Niaudet P, et al. Successful kidney transplantation of immunized patients after desimmunization with normal human polyclonal immunoglobulins for intravenous use (IVIg). J Am Soc Nephrol 1993; 4: 937.
13. Glotz, D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758.
14. Glotz, D, Antoine C, Julia P, et al. A prospective trial of the use of intravenous immunoglobulins (IVIg) in immunized patients waiting for a renal allograft. J Am Soc Nephrol 1999; 10: 730A.
15. Jordan SC. Management of the highly HLA-sensitized patient. A novel role for intravenous gammaglobulin. Am J Transplant 2002; 2: 691.
16. Jordan SC, Tyan DB, Stablein DM, et al. Evaluation of intravenous immunoglobulin (IVIg) as an agent to lower allosensitization and improve transplantation in highly-sensitized adult ESRD patients: report of the NIH IG02 trial. In American Transplant Congress. 2003. Washington, D.C.
17. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887.
18. Sonnenday CJ, Graziani J, Zachary AA, et al. Characterization of acute rejection episodes following pre-emptive plasmapheresis/CMVIg to abrogate a positive crossmatch and allow live donor renal transplantation. In American Transplant Congress. 2003. Washington.
19. Sonnenday CJ, Ratner LE, Zachary AA, et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002; 34: 1614.
20. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a Positive Crossmatch in Living-Donor Kidney Transplantation. Am J Transplant 2003; 3: 1017.
21. Gloor JM, Moore SB, Pineda AA, et al. Living donor kidney transplantation in positive crossmatch patients. In American Transplant Congress. 2003. Washington.
22. Robinson JA, Radvany RM, Mullen MG and Garrity ER Jr. Plasmapheresis followed by intravenous immunoglobulin in presensitized patients awaiting thoracic organ transplantation. Ther Apher 1997; 1: 147.
23. McIntyre JA, Higgins N, Britton R, et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis. Transplantation 1996; 62: 691.
24. Itescu S, Burke E, Lietz K, et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 2002; 105: 1214.
25. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542.
26. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75: 971.
27. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800.
28. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72: 419.
29. Rocha PN, Butterly DW, Greenberg A, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75: 1490.
30. Theruvath TP, Saidman SL, Mauiyyedi S, et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72: 77.
31. Nickeleit V, Zeiler M, Gudat F, et al. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: 242.
32. Salama AD, Delikouras A, Pusey CD, et al. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260.